Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective.

Abstract

Simple SummaryDespite recent progress in the treatment of metastatic colorectal cancer patients, novel therapeutic approaches are highly warranted to further improve outcome. Additionally, it is of utmost importance to define subgroups of patients who may derive the most benefit from a specific treatment, as we are moving forward in the field of personalized medicine. This review provides an overview about established biomarkers helping us to better guide treatment. Moreover, we report on emerging and potential promising biomarkers having the potential to be implemented into clinical practice in the near future.Colorectal cancer (CRC) is the third most frequent cancer worldwide, and its incidence is steadily increasing. During the last two decades, a tremendous improvement in outcome has been achieved, mainly due to the introduction of novel drugs, targeted treatment, immune checkpoint inhibitors (CPIs) and biomarker-driven patient selection. Moreover, progress in molecular diagnostics but also improvement in surgical techniques and local ablative treatments significantly contributed to this success. However, novel therapeutic approaches are needed to further improve outcome in patients diagnosed with metastatic CRC. Besides the established biomarkers for mCRC, such as microsatellite instability (MSI) or mismatch repair deficiency (dMMR), RAS/BRAF, sidedness and HER2 amplification, new biomarkers have to be identified to better select patients who derive the most benefit from a specific treatment. In this review, we provide an overview about therapeutic relevant and established biomarkers but also shed light on potential promising markers that may help us to better tailor therapy to the individual mCRC patient in the near future.